Global Varicella Attenuated Live Vaccine 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR062501670

Publication Date:

June 16, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Varicella Attenuated Live Vaccine market size was valued at US$ 2857 million in 2024 and is forecast to a readjusted size of USD 3798 million by 2031 with a CAGR of 4.2% during review period.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
This report is a detailed and comprehensive analysis for global Varicella Attenuated Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Varicella Attenuated Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2020-2031
Global Varicella Attenuated Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2020-2031
Global Varicella Attenuated Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2020-2031
Global Varicella Attenuated Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Doses), and ASP (USD/Dose), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Varicella Attenuated Live Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Varicella Attenuated Live Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech, Changchun Changsheng Life Sciences Limited, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Varicella Attenuated Live Vaccine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Monovalent Vaccine
Combination Vaccine
麻豆原创 segment by Application
Kids Injection
Adults Injection
Major players covered
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Varicella Attenuated Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Varicella Attenuated Live Vaccine, with price, sales quantity, revenue, and global market share of Varicella Attenuated Live Vaccine from 2020 to 2025.
Chapter 3, the Varicella Attenuated Live Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Varicella Attenuated Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Varicella Attenuated Live Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Varicella Attenuated Live Vaccine.
Chapter 14 and 15, to describe Varicella Attenuated Live Vaccine sales channel, distributors, customers, research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Varicella Attenuated Live Vaccine Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Monovalent Vaccine
1.3.3 Combination Vaccine
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Varicella Attenuated Live Vaccine Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Kids Injection
1.4.3 Adults Injection
1.5 Global Varicella Attenuated Live Vaccine 麻豆原创 Size & Forecast
1.5.1 Global Varicella Attenuated Live Vaccine Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Varicella Attenuated Live Vaccine Sales Quantity (2020-2031)
1.5.3 Global Varicella Attenuated Live Vaccine Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Varicella Attenuated Live Vaccine Product and Services
2.1.4 Merck Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Merck Recent Developments/Updates
2.2 BCHT
2.2.1 BCHT Details
2.2.2 BCHT Major Business
2.2.3 BCHT Varicella Attenuated Live Vaccine Product and Services
2.2.4 BCHT Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 BCHT Recent Developments/Updates
2.3 Shanghai Institute
2.3.1 Shanghai Institute Details
2.3.2 Shanghai Institute Major Business
2.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Product and Services
2.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Shanghai Institute Recent Developments/Updates
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business
2.4.3 GSK Varicella Attenuated Live Vaccine Product and Services
2.4.4 GSK Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 GSK Recent Developments/Updates
2.5 Keygen
2.5.1 Keygen Details
2.5.2 Keygen Major Business
2.5.3 Keygen Varicella Attenuated Live Vaccine Product and Services
2.5.4 Keygen Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Keygen Recent Developments/Updates
2.6 Green Cross
2.6.1 Green Cross Details
2.6.2 Green Cross Major Business
2.6.3 Green Cross Varicella Attenuated Live Vaccine Product and Services
2.6.4 Green Cross Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Green Cross Recent Developments/Updates
2.7 Biken
2.7.1 Biken Details
2.7.2 Biken Major Business
2.7.3 Biken Varicella Attenuated Live Vaccine Product and Services
2.7.4 Biken Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Biken Recent Developments/Updates
2.8 Shanghai Rongsheng Biotech
2.8.1 Shanghai Rongsheng Biotech Details
2.8.2 Shanghai Rongsheng Biotech Major Business
2.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product and Services
2.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Shanghai Rongsheng Biotech Recent Developments/Updates
2.9 Changchun Changsheng Life Sciences Limited
2.9.1 Changchun Changsheng Life Sciences Limited Details
2.9.2 Changchun Changsheng Life Sciences Limited Major Business
2.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product and Services
2.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Changchun Changsheng Life Sciences Limited Recent Developments/Updates
3 Competitive Environment: Varicella Attenuated Live Vaccine by Manufacturer
3.1 Global Varicella Attenuated Live Vaccine Sales Quantity by Manufacturer (2020-2025)
3.2 Global Varicella Attenuated Live Vaccine Revenue by Manufacturer (2020-2025)
3.3 Global Varicella Attenuated Live Vaccine Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Varicella Attenuated Live Vaccine by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Varicella Attenuated Live Vaccine Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Varicella Attenuated Live Vaccine Manufacturer 麻豆原创 Share in 2024
3.5 Varicella Attenuated Live Vaccine 麻豆原创: Overall Company Footprint Analysis
3.5.1 Varicella Attenuated Live Vaccine 麻豆原创: Region Footprint
3.5.2 Varicella Attenuated Live Vaccine 麻豆原创: Company Product Type Footprint
3.5.3 Varicella Attenuated Live Vaccine 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Varicella Attenuated Live Vaccine 麻豆原创 Size by Region
4.1.1 Global Varicella Attenuated Live Vaccine Sales Quantity by Region (2020-2031)
4.1.2 Global Varicella Attenuated Live Vaccine Consumption Value by Region (2020-2031)
4.1.3 Global Varicella Attenuated Live Vaccine Average Price by Region (2020-2031)
4.2 North America Varicella Attenuated Live Vaccine Consumption Value (2020-2031)
4.3 Europe Varicella Attenuated Live Vaccine Consumption Value (2020-2031)
4.4 Asia-Pacific Varicella Attenuated Live Vaccine Consumption Value (2020-2031)
4.5 South America Varicella Attenuated Live Vaccine Consumption Value (2020-2031)
4.6 Middle East & Africa Varicella Attenuated Live Vaccine Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Varicella Attenuated Live Vaccine Sales Quantity by Type (2020-2031)
5.2 Global Varicella Attenuated Live Vaccine Consumption Value by Type (2020-2031)
5.3 Global Varicella Attenuated Live Vaccine Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Varicella Attenuated Live Vaccine Sales Quantity by Application (2020-2031)
6.2 Global Varicella Attenuated Live Vaccine Consumption Value by Application (2020-2031)
6.3 Global Varicella Attenuated Live Vaccine Average Price by Application (2020-2031)
7 North America
7.1 North America Varicella Attenuated Live Vaccine Sales Quantity by Type (2020-2031)
7.2 North America Varicella Attenuated Live Vaccine Sales Quantity by Application (2020-2031)
7.3 North America Varicella Attenuated Live Vaccine 麻豆原创 Size by Country
7.3.1 North America Varicella Attenuated Live Vaccine Sales Quantity by Country (2020-2031)
7.3.2 North America Varicella Attenuated Live Vaccine Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Varicella Attenuated Live Vaccine Sales Quantity by Type (2020-2031)
8.2 Europe Varicella Attenuated Live Vaccine Sales Quantity by Application (2020-2031)
8.3 Europe Varicella Attenuated Live Vaccine 麻豆原创 Size by Country
8.3.1 Europe Varicella Attenuated Live Vaccine Sales Quantity by Country (2020-2031)
8.3.2 Europe Varicella Attenuated Live Vaccine Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Varicella Attenuated Live Vaccine Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Varicella Attenuated Live Vaccine Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Varicella Attenuated Live Vaccine 麻豆原创 Size by Region
9.3.1 Asia-Pacific Varicella Attenuated Live Vaccine Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Varicella Attenuated Live Vaccine Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Varicella Attenuated Live Vaccine Sales Quantity by Type (2020-2031)
10.2 South America Varicella Attenuated Live Vaccine Sales Quantity by Application (2020-2031)
10.3 South America Varicella Attenuated Live Vaccine 麻豆原创 Size by Country
10.3.1 South America Varicella Attenuated Live Vaccine Sales Quantity by Country (2020-2031)
10.3.2 South America Varicella Attenuated Live Vaccine Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Varicella Attenuated Live Vaccine Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Varicella Attenuated Live Vaccine 麻豆原创 Size by Country
11.3.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Varicella Attenuated Live Vaccine Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Varicella Attenuated Live Vaccine 麻豆原创 Drivers
12.2 Varicella Attenuated Live Vaccine 麻豆原创 Restraints
12.3 Varicella Attenuated Live Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Varicella Attenuated Live Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Varicella Attenuated Live Vaccine
13.3 Varicella Attenuated Live Vaccine Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Varicella Attenuated Live Vaccine Typical Distributors
14.3 Varicella Attenuated Live Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Companies Mentioned:

Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.